Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion type Assertion NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_head.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion description "[The 6-month overall survival rate of 36% observed on this study failed to meet the primary survival objective. Thus, cetuximab alone cannot be recommended in the second-line treatment of metastatic esophageal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_provenance.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion evidence source_evidence_literature NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_provenance.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion SIO_000772 20631636 NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_provenance.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion wasDerivedFrom gad-20150221 NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_provenance.
- NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_assertion wasGeneratedBy ECO_0000203 NP181583.RAZ4rKDMzKlzFxjV0-HslV4rXZrtv3f-0DQBFV2s4cohU130_provenance.